Biotechnology

Wednesday Feb 16, 2022 - 3:19 pm

InvestorNewsBreaks – Red White & Bloom Brands Inc.’s (CSE: RWB) (OTCQX: RWBYF) Warren Facility Providing Centralized Distribution, Production Capacity to Expand Sales

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) has received full licensing for manufacturing both medical and adult-use cannabis products in Michigan, a state entering its third year under legislation allowing the legal sale of adult recreational-use cannabis. In addition, a recent article notes, “The company has closed on a lease assignment for a 15,000-square-foot manufacturing, processing and distribution facility in Warren, Michigan, which…

Wednesday Feb 16, 2022 - 11:12 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Evolution to Commercial Sales to Health and Wellness Market Featured in Research Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. According to the piece, InMed achieved Q222 financial results that reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0.3…

Wednesday Feb 16, 2022 - 11:04 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Adds Novel Molecule to Family of Psilocin Analogs

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has included a novel molecule — MYCO-005 — which has potential for heart-safe microdose enabling properties, to its psilocin analogs. The company submitted a patent application covering multiple families of psilocin analogs late last year, noting that these second-generation molecules address delivery and stability concerns…

Tuesday Feb 15, 2022 - 3:21 pm

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Distinctive with Phased Approach to Novel Therapeutics Development

Mydecine (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent Bell2Bell Podcast episode in which its co-founder, chairman and CEO Josh Bartch shared the company’s goals for the new year. Of note was Mydecine’s phased approach, which entails understanding the imperfections of initial formulations and then improving aspects…

Tuesday Feb 15, 2022 - 10:18 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has appointed Gerard (Jerry) P. Griffin III as vice president of sales and marketing at BayMedica, a wholly owned subsidiary of InMed. In his new role, Griffin will manage the commercialization of BayMedica’s health and wellness business including existing products as well as the launch of new products. Griffin…

Monday Feb 14, 2022 - 10:48 am

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Reports Financial Results, Business Updates for Q3 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, has released its Q3 financial results and business updates. The company noted that, for the three-month period ending Dec. 31, 2021, highlights included the shipment of sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its United-Kingdom licensee, MySugarWatch Limited; the appointment of Dr. Arash Ghadar…

Friday Feb 11, 2022 - 12:37 pm

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Appoints New COO in Readiness for Manufacturing and Distribution Scale-Up, Commercialization Phase of Growth

Nemaura Medical (NASDAQ: NMRD) recently appointed Dr. Arash Ghadar as its chief operating officer. Dr. Ghadar brings decades of health care and technical experience to Nemaura, including from his previous role as technical director at Datalink Electronics and his current director role at Medilink Midlands. “Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations… He…

Thursday Feb 10, 2022 - 10:04 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release Q2 Financial Report, Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced that it will report its second-quarter financial results next week on Feb. 15, 2022; the results will cover the period ending Dec. 31, 2021. The company has scheduled a conference call and webcast to discuss the report; the call will be held Feb. 15, 2021, at 2 p.m.…

Tuesday Feb 08, 2022 - 11:55 am

InvestorNewsBreaks – Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Exclusive Dealer Identified as Supplier for Health Canada’s Special Access Program

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company aiming to transform the treatment of mental health and addiction disorders. The company today announced that Health Canada has included the dealer’s license Mydecine operates under as a supplier for the Special Access Program (“SAP”), which allows health care providers to request specific drugs for approved patients who have not responded to other treatment…

Thursday Feb 03, 2022 - 3:38 pm

InvestorNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Miboko Launch Leveraging ‘Most Reliable Gateway Toward Wider Adoption of Preventative Health Maintenance Practices’

Nemaura Medical (NASDAQ: NMRD) recently announced it would launch Miboko, its new metabolic health program, for employers and insurers. “The Miboko application, a service offering that has been in development over the past 18 months, uses a non-invasive glucose sensor to measure and monitor users’ blood sugar levels, which are based on glucose tolerance or insulin resistance. The device is linked to an AI mobile…

Thursday Feb 03, 2022 - 10:25 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Strengthens Board with Appointment of Dr. Victoria Hale

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s board of directors. A pharmaceutical scientist, executive and global health social entrepreneur, Dr. Hale currently serves as chair of the board of the Multidisciplinary Association for Psychedelic Studies (“MAPS”). A non-profit research and…

Wednesday Feb 02, 2022 - 2:57 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Blazing Trail in Defining Value of Rare Cannabinoids in Pharmaceutical Space

InMed Pharmaceuticals (NASDAQ: INM) is a trailblazer, a pioneer defining the value of rare cannabinoids in the pharmaceutical sector and just how integral they are in pushing the industry forward. The global cannabis market is experiencing tremendous growth, particularly considering there are over 100 known cannabinoids, including rare ones that are quickly taking over and will soon dominate the market. The potency of rare cannabinoids…

Wednesday Feb 02, 2022 - 2:45 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Laying Robust Foundation for Potentially Pivotal Global Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently received approval from swissethics, the umbrella organization of the cantonal Ethics Committees in Switzerland. The first from a European Ethics Committee, the approval marks a significant milestone for the company as it journeys toward its potentially pivotal study of Berubicin, an anthracycline, for the treatment of Glioblastoma Multiforme (“GBM”). The approval also partly fulfills CNS’s goal of seeing Berubicin approved…

Tuesday Feb 01, 2022 - 10:45 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) at the Forefront of Research Investigating Psilocybin Compound for Smoking Cessation

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. Mydecine has announced that, in preparation for its FDA pre-Investigational New Drug (“IND”) meeting on Feb. 28, the company has submitted a pre-IND briefing package to the U.S. Food and Drug Administration (“FDA”) for a clinical study evaluating MYCO-001 in…

Monday Jan 31, 2022 - 3:33 pm

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Bringing Safer, More Effective Nicotine Dependence Treatment to Market

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is in an excellent position to tap into the opportunities offered by the smoking cessation market. In early 2021, one of the leading smoking cessation tools prescribed by physicians, Chantix, was pulled off the market for its cancer risk, leaving a large hole…

Monday Jan 31, 2022 - 12:21 pm

InvestorNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) Partners with Renowned Expert to Discuss Alcohol Use Disorder and Trauma at Upcoming Virtual Event

Clearmind Medicine (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) is a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems. The company has announced that, as part of its “Psychedelics for Alcoholism” events series, it will host Dr. Gabor Maté to discuss alcohol use disorder and how Clearmind’s candidate treatment may create a clear path to…

Tuesday Jan 25, 2022 - 10:43 am

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Ranked No. 1 Globally in Multi-Cancer Screening and Detection Test Volume

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that Frost & Sullivan Company, a leading and well-known U.S. market analysis and research firm, has ranked AnPac Bio globally as number one in worldwide multiple cancer screening and detection volume in a recent research report. Based on data accumulated through the end of 2020, the report included…

Monday Jan 24, 2022 - 12:28 pm

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Partnership to Treat PTSD in Veterans

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced a partnership with Combat Stress and the King's College London to utilize psilocybin as part of a psychoactive-assisted psychotherapy treatment for post-traumatic stress disorder (“PTSD”) in veterans. According to the update, Combat Stress, the leading charity aiding veterans’ mental…

Wednesday Jan 19, 2022 - 10:20 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that it has launched B2B sales of the rare cannabinoid cannabicitran (“CBT”) into the health and wellness sector. According to the update, CBT is the first of several new product launches the company has planned for the first half of 2022. “We are delivering on our objective…

Tuesday Jan 18, 2022 - 12:13 pm

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), The Newly Partner to Set the Gold Standard for Psychedelic-Assisted Therapies

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into a letter of intent (“LOI”) with The Newly Institute Inc. (“The Newly”), a Calgary, Alberta based company opening private inter-disciplinary mental health clinics across Canada. The companies will collaborate on expanding psychedelic-assisted psychotherapy to patients and,…

Thursday Jan 13, 2022 - 12:52 pm

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Launches Miboko – a New Metabolic Health Program

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the launch of Miboko for employers and insurers. Miboko is a new metabolic health program using a non-invasive glucose sensor along with an AI mobile application. The company, aligned with the general trend in consumer digital health care, aims to…

Thursday Jan 13, 2022 - 10:27 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Launches Canadian Program to Support Psychedelic-Assisted Psychotherapy

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has unveiled its Special Access Support and Supply Program (“SASSP”). The program provides products, services and support to hospitals, clinics and physicians in Canada who utilize psychedelic-assisted psychotherapy treatment. Health Canada recently added psilocybin and MDMA to its approved list of…

Tuesday Jan 11, 2022 - 1:20 pm

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Featured in Latest Episode of Bell2Bell Podcast

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, was featured in the Bell2Bell Podcast, a part of IBN’s (“InvestorBrandNetwork”) sustained effort to provide specialized content distribution via widespread syndication channels. Mydecine’s co-founder, chairman and CEO Josh Bartch joined the latest episode to discuss the company’s business model, highlighting its…

Tuesday Jan 11, 2022 - 9:30 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Closes on $11.5M Private Placement

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has closed on its previously announced private placement. The company announced that the placement was comprised of 12,105,264 shares of common stock (or prefunded warrants) and warrants at a purchase at $0.95 per share or warrant. The placement was…

Monday Jan 10, 2022 - 9:52 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Engages JBN Partners LLC, Completes Target-Based Model for AI-Driven Drug Discovery Program

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, has announced its engagement of JBN Partners LLC to increase public awareness of and interest in the company, its management and its products. Under the collaboration, JBN will coordinate certain investor relations and corporate financial public relations with members of the…

Friday Jan 07, 2022 - 10:32 am

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at H.C. Wainwright Bioconnect Conference

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that its CEO Dr. Faz Chowdhury will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference. The event is slated to take place on Jan. 10-13, 2022, with Dr. Chowdhury’s presentation available on-demand to registered attendees beginning…

Friday Jan 07, 2022 - 10:20 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate at H.C. Wainwright BioConnect Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that CEO John Climaco will present at the upcoming H.C. Wainwright BioConnect Conference. The conference is slated for Jan. 10-13, 2022. Interested parties who have registered for the event can view the presentation, which will be virtual, at…

Thursday Jan 06, 2022 - 1:53 pm

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) Featured on ‘Gamechangers LIVE’

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, was featured in a recent episode of “Gamechangers LIVE.” The podcast series shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners.…

Thursday Jan 06, 2022 - 11:44 am

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), Announces Participation in Upcoming H.C. Wainwright Bioconnect Conference

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, will be participating in the H.C. Wainwright Bioconnect Conference; the multiday conference is scheduled for Jan. 10–13, 2022. According to the announcement, MINDCURE president and CEO Kelsey Ramsden will provide a virtual presentation, which will be available for viewing beginning on Monday, Jan. 10, 2022, at 7…

Thursday Jan 06, 2022 - 9:59 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Agreements Totaling $11.5M for Gross Proceeds

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (“CNS”), has entered into securities purchase agreements with several institutional and accredited investors. The agreements outline the issue of more than 12 million shares of common stock, prefunded warrants and warrants in a private placement; the shares and warrants…

Wednesday Jan 05, 2022 - 2:31 pm

InvestorNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) Innovative Portfolio Powers Research Insights

RYAH Group (CSE: RYAH) is the leader in volume-control technology for plant-based medicine. The company supports cannabis research for the treatment of cancer “with innovative technology that collects, analyzes and leverages objective data on therapeutic plant usage. By using the company’s smart devices and integrated AI-powered platform, patients and doctors can stay on top of prescription treatments in a safe, secure and seamless way,” reads…

Wednesday Jan 05, 2022 - 10:21 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Annual Shareholder Letter Provides Company Highlights, 2022 Outlook

InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, has released a shareholder letter. The letter, from president and CEO Eric A. Adams, provided INM shareholders with a company update, including a look at key milestones the company had reached, including the acquisition of BayMedica, which Adams said positioned InMed as a clear leader in rare cannabinoid manufacturing. Adams…

Tuesday Jan 04, 2022 - 1:45 pm

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Marks True Milestone in Development, Growth

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently completed the initial shipment of its sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its U.K. licensee, MySugarWatch Limited. “MySugarWatch will market the sugarBEAT product under the MySugarWatch(R) brand and has developed a subscription-based diabetes coaching and management service packaged alongside the…

Tuesday Jan 04, 2022 - 11:01 am

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Proprietary Medical Device Passes Registration Tests, Slated to Start Clinical Trial

AnPac Bio-Medical Science (NASDAQ: ANPC), a U.S.- and China-based biotechnology company focused on early cancer screening and detection, announced that its Class III medical device for lung cancer auxiliary diagnosis has passed stringent and rigorous registration tests; the tests were conducted at a testing laboratory selected by China’s regulatory agent for medical products, the National Medical Products Administration (“NMPA”). The device passed tests designed to…

Thursday Dec 30, 2021 - 11:52 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Expanding Robust Portfolio of Novel Compounds

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company, has aimed to transform the treatment of mental health disorders and addiction since its inception. The company has already developed first- and second-generation novel therapeutics designed to treat addiction, post-traumatic stress disorder (“PTSD”) and other mental health conditions. “Mydecine recently released its third-quarter 2021 update and a noteworthy announcement for the 2021 calendar year.…

Wednesday Dec 29, 2021 - 12:18 pm

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Bringing Solutions to Empower People to Take Charge of Their Health, Well-Being

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. Since its founding in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved to create wearable technologies and digital health care solutions that encourage…

Monday Dec 27, 2021 - 1:42 pm

InvestorNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) Smart Dry Herb Inhaler Providing Consistent, Predictable Results

RYAH Group (CSE: RYAH) develops innovative IoT products that capture powerful data insights and is on a mission to transform patient care using big data and AI to reshape the understanding and uses of plant-based medicines. The company’s devices and data are being used by a rapidly growing number of participants in plant-based clinical trials around the world, including clinical research into the relationship between…

Monday Dec 20, 2021 - 2:20 pm

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Standing Distinct in Advancing Psychedelic Medicine

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) recently released financials and a business update for the third quarter ending Sept. 30, 2021. During this reporting period, the company filed three patent applications; successfully synthesized a novel psilocin analogue with improved pharmaceutical properties; launched Mindleap 2.0, an updated version of its proprietary virtual health platform; and completed its spin-out transaction of ALT House Cannabis Inc. “The…

Monday Dec 20, 2021 - 1:58 pm

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Advancing Core Research, Commercial Production Programs, Identifying Pipeline Expansion Opportunities

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, recently provided an update sharing significant milestones reached in 2021 for both of its operating arms, MINDCURE Research and MINDCURE Technology. MINDCURE Research offered several updates, including important milestones in its synthetic ibogaine manufacturing; the company is currently on schedule to provide Good Laboratory Practice (“GLP”) ibogaine…

Monday Dec 20, 2021 - 10:17 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces General Meeting Voting, Publication of Key Article on CBN as Possible Glaucoma Treatment

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, held its general meeting on Dec. 17, 2021, and approved the election of all director nominees. Those elected will hold office until the next annual shareholder meeting or until their successors are elected or appointed. The company also noted that all of the matters outlined for consideration and approval in…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions